Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shreve, P.
Right arrow Articles by Wahl, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shreve, P.
Right arrow Articles by Wahl, R.

Radiology, Vol 199, 751-756, Copyright © 1996 by Radiological Society of North America

ARTICLES

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F- 18]fluoro-D-glucose

PD Shreve, HB Grossman, MD Gross and RL Wahl
Nuclear Medicine Service, Department of Veterans Affairs Medical Center, Ann Arbor, Mich, USA.

PURPOSE: To evaluate the accuracy of positron emission tomography (PET) with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (FDG) in the detection of osseous and soft-tissue metastases of prostate cancer. MATERIALS AND METHODS: Thirty-four patients (mean age, 71 years) with biopsy-proved prostate cancer and known or suspected metastatic disease were examined. Blinded interpretation of the PET images was compared with bone scan, CT, and clinical follow-up findings. RESULTS: In 202 untreated osseous metastases in 22 patients, the sensitivity of FDG PET was 65% (131 of 202 metastases), with a positive predictive value of 98% (131 of 133 positive findings). The estimated standardized uptake value in metastases was 2.1-5.7. Soft-tissue metastases to the lymph nodes or liver were identified, but evaluation of pelvic lymph node metastases was severely limited because of bladder tracer activity. CONCLUSION: FDG PET can help identify osseous and soft-tissue metastases of prostate cancer with a high positive predictive value but is less sensitive than bone scintigraphy in the identification of osseous metastases.


This article has been cited by other articles:


Home page
 JNMHome page
W. K. Hsu, M. S. Virk, B. T. Feeley, D. B. Stout, A. F. Chatziioannou, and J. R. Lieberman
Characterization of Osteolytic, Osteoblastic, and Mixed Lesions in a Prostate Cancer Mouse Model Using 18F-FDG and 18F-Fluoride PET/CT
J. Nucl. Med., March 1, 2008; 49(3): 414 - 421.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Basu and A. Alavi
Bone Marrow and Not Bone Is the Primary Site for Skeletal Metastasis: Critical Role of [18F]Fluorodeoxyglucose Positron Emission Tomography in This Setting
J. Clin. Oncol., April 1, 2007; 25(10): 1297 - 1297.
[Full Text] [PDF]

Home page
 RadiologyHome page
H. Hricak, P. L. Choyke, S. C. Eberhardt, S. A. Leibel, and P. T. Scardino
Imaging Prostate Cancer: A Multidisciplinary Perspective
Radiology, April 1, 2007; 243(1): 28 - 53.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. E. Ponde, C. S. Dence, N. Oyama, J. Kim, Y.-C. Tai, R. Laforest, B. A. Siegel, and M. J. Welch
18F-Fluoroacetate: A Potential Acetate Analog for Prostate Tumor Imaging--In Vivo Evaluation of 18F-Fluoroacetate Versus 11C-Acetate
J. Nucl. Med., March 1, 2007; 48(3): 420 - 428.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. M. Schuster, J. R. Votaw, P. T. Nieh, W. Yu, J. A. Nye, V. Master, F. D. Bowman, M. M. Issa, and M. M. Goodman
Initial Experience with the Radiotracer Anti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid with PET/CT in Prostate Carcinoma
J. Nucl. Med., January 1, 2007; 48(1): 56 - 63.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, and I. Leibovitch
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT
J. Nucl. Med., February 1, 2006; 47(2): 287 - 297.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Even-Sapir
Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
N. Subhas, P. V. Patel, H. K. Pannu, H. A. Jacene, E. K. Fishman, and R. L. Wahl
Imaging of Pelvic Malignancies with In-Line FDG PET-CT: Case Examples and Common Pitfalls of FDG PET
RadioGraphics, July 1, 2005; 25(4): 1031 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Morris, T. Akhurst, S. M. Larson, M. Ditullio, E. Chu, K. Siedlecki, D. Verbel, G. Heller, W. K. Kelly, S. Slovin, et al.
Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy
Clin. Cancer Res., May 1, 2005; 11(9): 3210 - 3216.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
F. Y.-I. Lee, J. Yu, S.-S. Chang, R. Fawwaz, and M. V. Parisien
Diagnostic Value and Limitations of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Cartilaginous Tumors of Bone
J. Bone Joint Surg. Am., December 1, 2004; 86(12): 2677 - 2685.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno
Bone Imaging in Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Oyama, D. E. Ponde, C. Dence, J. Kim, Y.-C. Tai, and M. J. Welch
Monitoring of Therapy in Androgen-Dependent Prostate Tumor Model by Measuring Tumor Proliferation
J. Nucl. Med., March 1, 2004; 45(3): 519 - 525.
[Abstract] [Full Text]

Home page
 JNMHome page
E. Even-Sapir, U. Metser, G. Flusser, L. Zuriel, Y. Kollender, H. Lerman, G. Lievshitz, I. Ron, and E. Mishani
Assessment of Malignant Skeletal Disease: Initial Experience with 18F-Fluoride PET/CT and Comparison Between 18F-Fluoride PET and 18F-Fluoride PET/CT
J. Nucl. Med., February 1, 2004; 45(2): 272 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. W. Fosko, W. Hu, T. F. Cook, and V. J. Lowe
Positron Emission Tomography for Basal Cell Carcinoma of the Head and Neck
Arch Dermatol, September 1, 2003; 139(9): 1141 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru
Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer
J. Nucl. Med., May 1, 2003; 44(5): 690 - 699.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Oyama, T. R. Miller, F. Dehdashti, B. A. Siegel, K. C. Fischer, J. M. Michalski, A. S. Kibel, G. L. Andriole, J. Picus, and M. J. Welch
11C-Acetate PET Imaging of Prostate Cancer: Detection of Recurrent Disease at PSA Relapse
J. Nucl. Med., April 1, 2003; 44(4): 549 - 555.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Dimitrakopoulou-Strauss and L. G. Strauss
PET Imaging of Prostate Cancer with 11C-Acetate
J. Nucl. Med., April 1, 2003; 44(4): 556 - 558.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Morris and H. I. Scher
Clinical Approaches to Osseous Metastases in Prostate Cancer
Oncologist, April 1, 2003; 8(2): 161 - 173.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
I. J. de Jong, J. Pruim, P. H. Elsinga, W. Vaalburg, and H. J. Mensink
Preoperative Staging of Pelvic Lymph Nodes in Prostate Cancer by 11C-Choline PET
J. Nucl. Med., March 1, 2003; 44(3): 331 - 335.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Wakasugi, A. Noguti, T. Katuda, T. Hashizume, and Y. Hasegawa
Potential of 99mTc-MIBI for Detecting Bone Marrow Metastases
J. Nucl. Med., May 1, 2002; 43(5): 596 - 602.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Kotzerke, J. E. Gschwend, and B. Neumaier
PET for Prostate Cancer Imaging: Still a Quandary or the Ultimate Solution?
J. Nucl. Med., February 1, 2002; 43(2): 200 - 202.
[Full Text] [PDF]

Home page
 JNMHome page
R. Nunez, H. A. Macapinlac, H. W.D. Yeung, T. Akhurst, S. Cai, I. Osman, M. Gonen, E. Riedel, H. I. Scher, and S. M. Larson
Combined 18F-FDG and 11C-Methionine PET Scans in Patients with Newly Progressive Metastatic Prostate Cancer
J. Nucl. Med., January 1, 2002; 43(1): 46 - 55.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. R. DeGrado, S. W. Baldwin, S. Wang, M. D. Orr, R. P. Liao, H. S. Friedman, R. Reiman, D. T. Price, and R. E. Coleman
Synthesis and Evaluation of 18F-Labeled Choline Analogs as Oncologic PET Tracers
J. Nucl. Med., December 1, 2001; 42(12): 1805 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps
A Tabulated Summary of the FDG PET Literature
J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93.
[Full Text] [PDF]

Home page
 JNMHome page
C. Messa, C. Landoni, C. Pozzato, and F. Fazio
Is There a Role for FDG PET in the Diagnosis of Musculoskeletal Neoplasms?
J. Nucl. Med., October 1, 2000; 41(10): 1702 - 1702.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
T. R. DeGrado, R. E. Coleman, S. Wang, S. W. Baldwin, M. D. Orr, C. N. Robertson, T. J. Polascik, and D. T. Price
Synthesis and Evaluation of 18F-labeled Choline as an Oncologic Tracer for Positron Emission Tomography: Initial Findings in Prostate Cancer
Cancer Res., January 1, 2000; 61(1): 110 - 117.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1996 by the Radiological Society of North America.